Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

Figures & data

Figure 1 Iron overload and its effects in myelodysplastic syndrome.

Table 1 Principal Studies on Deferasirox in Low-risk MDS Patients

Author (Year)	Study Type	Patients N	Dosage (mg/kg/Day)	Ferritin at Baseline ng/mL (Median)	Ferritin at 12th Month ng/mL (Median)	p	Adverse Events	Erythroid Response (%)
Gattermann (2010) EPIC^Citation91	Phase IIIb prospective multicenter openlabel single-arm	341	10–30	2730	1904	0.002	GI, skin rash	22.6
Angelucci (2014) GIMEMA MDS0306^Citation92	Prospective, open-label, single-arm, multicenter trial	152	10–20	1966	1475	<0.0001	GI, renal	15.5
Nolte (2013)^Citation93	Open-label, single arm, multicenter trial	50	20–30	2447	1685	0.01	GI, renal, skin rash	11.0
List (2009)-US03^Citation100	Phase II, open-label	176	20	2771	2210	<0.001	GI, renal	15.0
Maurillo (2015)^Citation95	Retrospective	118	10–20	1773	1300	<0.001	GI, renal	19.0
Breccia (2012)^Citation96	Single-institution experience	40	10–30	2878	1400	<0.001	GI, skin rash	10.0
Gattermann (2012)- EXTEND^Citation97	Prospective, 1-year, noninterventional, observational, multicentre	123	10–20	2679	2000	0.0002	GI, renal, skin rash	NR
Gattermann (2012)- EXJANGE^Citation97	Prospective, 1-year, non-interventional, observational, multicenter	44	10–30	2442	2077	0.06	GI, renal, skin rash	NR

Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–1150. doi:10.1016/j.leukres.2010.03.009

 PubMed Web of Science ®Google Scholar

Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92:527–536. doi:10.1111/ejh.12300

 PubMed Web of Science ®Google Scholar

Nolte F, Hochsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013;92:191–198. doi:10.1007/s00277-012-1594-z

 PubMed Web of Science ®Google Scholar

List AF, Baer MR, Steensma D, et al. Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood. 2008;112(11):523a.

 Web of Science ®Google Scholar

Maurillo L, Breccia M, Buccisano F, et al. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a ‘realworld’ report from two regional Italian registries: gruppo Romano Mielodisplasie and Registro Basilicata. Eur J Haematol. 2015;95:52–56. doi:10.1111/ejh.12476

 PubMed Web of Science ®Google Scholar

Breccia M, Fisinger P, Loglisci G, et al. Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Haematol. 2012;91:1345–1349. doi:10.1007/s00277-012-1481-7

 PubMed Web of Science ®Google Scholar

Gattermann N, Jarish A, Shlag R, et al. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies Extend and EXJjange. Eur J Haematol. 2012;88(3):260–268. doi:10.1111/j.1600-0609.2011.01726.x

 PubMed Web of Science ®Google Scholar